Related Experiment Video
Updated: May 7, 2026
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
Published on: November 4, 2022
Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy
Rafal Turo1, Samer Jallad, Stephen Prescott
1St. James University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
Abstract:
The incidence of prostate cancer in transsexual patients is very low with only few reported cases. Many years before presenting with prostate cancer, these patients receive hormone ablation as a part of their gender therapy. Their disease is already defined as castrate resistant, and the treatment and follow-up of such patients remains a challenge. We report a case of a male-to-female transgender woman who was diagnosed with metastatic prostate cancer, 31 years post-feminization.
Insights
Prostate cancer is rare in transgender individuals. This case highlights the challenges in diagnosing and treating metastatic prostate cancer in a male-to-female transgender patient long after gender-affirming hormone therapy.
Area of Science:
- Oncology
- Endocrinology
- Transgender Health
Background:
- Prostate cancer incidence is notably low in transgender populations.
- Transgender individuals often undergo hormone ablation as part of gender-affirming care.
- This can lead to pre-existing castrate resistance at the time of cancer diagnosis.
Purpose of the Study:
- To report a rare case of metastatic prostate cancer in a male-to-female transgender patient.
- To discuss the complexities in managing prostate cancer in transgender individuals.
- To highlight the long-term implications of feminization on prostate cancer presentation.
Main Methods:
- Case report of a male-to-female transgender woman.
- Review of medical history including feminization and hormone therapy.
- Diagnosis of metastatic prostate cancer 31 years post-feminization.
Main Results:
- A male-to-female transgender patient developed metastatic prostate cancer.
- The diagnosis occurred 31 years after feminization procedures and hormone therapy.
- The patient's condition was characterized as castrate-resistant.
Conclusions:
- Metastatic prostate cancer can occur in male-to-female transgender individuals decades after feminization.
- Managing prostate cancer in this population presents unique challenges due to prior hormone therapy.
- Further research is needed to understand prostate cancer development and treatment in transgender patients.
